| Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial G Németh, I Laszlovszky, P Czobor, E Szalai, B Szatmári, J Harsányi, ... The Lancet 389 (10074), 1103-1113, 2017 | 372 | 2017 |
| General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised … O Golubnitschaja, V Costigliola EPMA Journal 3 (1), 14, 2012 | 273 | 2012 |
| An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial S Durgam, A Starace, D Li, R Migliore, A Ruth, G Németh, I Laszlovszky Schizophrenia research 152 (2-3), 450-457, 2014 | 214 | 2014 |
| Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial S Durgam, AJ Cutler, K Lu, R Migliore, A Ruth, I Laszlovszky, G Németh, ... The Journal of clinical psychiatry 76 (12), 2310, 2015 | 192 | 2015 |
| An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression S Durgam, W Earley, A Lipschitz, H Guo, I Laszlovszky, G Németh, E Vieta, ... American Journal of Psychiatry 173 (3), 271-281, 2016 | 185 | 2016 |
| Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial GS Sachs, WM Greenberg, A Starace, K Lu, A Ruth, I Laszlovszky, ... Journal of affective disorders 174, 296-302, 2015 | 133 | 2015 |
| Efficacy and safety of low-and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study JR Calabrese, PE Keck, A Starace, K Lu, A Ruth, I Laszlovszky, G Németh, ... The Journal of clinical psychiatry 76 (3), 6179, 2014 | 132 | 2014 |
| The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial S Durgam, A Starace, D Li, R Migliore, A Ruth, G Németh, I Laszlovszky Bipolar disorders 17 (1), 63-75, 2015 | 124 | 2015 |
| Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major … S Durgam, W Earley, H Guo, D Li, G Németh, I Laszlovszky, M Fava, ... The Journal of clinical psychiatry 77 (3), 6112, 2016 | 123 | 2016 |
| Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study W Earley, MV Burgess, L Rekeda, R Dickinson, B Szatmári, G Németh, ... American Journal of Psychiatry 176 (6), 439-448, 2019 | 121 | 2019 |
| Akinetic mutism associated with bicingular lesions: clinicopathological and functional anatomical correlates G Németh, K Hegedüs, L Molnâr European archives of psychiatry and neurological sciences 237, 218-222, 1988 | 114 | 1988 |
| The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors W Fleischhacker, S Galderisi, I Laszlovszky, B Szatmári, Á Barabássy, ... European Psychiatry 58, 1-9, 2019 | 106 | 2019 |
| Cariprazine in the treatment of schizophrenia: a proof-of-concept trial S Durgam, RE Litman, K Papadakis, D Li, G Németh, I Laszlovszky International clinical psychopharmacology 31 (2), 61-68, 2016 | 86 | 2016 |
| Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study AJ Cutler, S Durgam, Y Wang, R Migliore, K Lu, I Laszlovszky, G Németh CNS spectrums 23 (1), 39-50, 2018 | 79 | 2018 |
| The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis HA Nasrallah, W Earley, AJ Cutler, Y Wang, K Lu, I Laszlovszky, ... BMC psychiatry 17, 1-13, 2017 | 76 | 2017 |
| Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study S Durgam, WM Greenberg, D Li, K Lu, I Laszlovszky, G Nemeth, ... Psychopharmacology 234, 199-209, 2017 | 70 | 2017 |
| Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data W Earley, H Guo, D Daniel, H Nasrallah, S Durgam, Y Zhong, M Patel, ... Schizophrenia research 204, 282-288, 2019 | 65 | 2019 |
| MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography M Bergström, G Németh European Journal of Clinical Pharmacology 52 (Issue 2,), Pages 121-128, 1997 | 58 | 1997 |
| Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety I Laszlovszky, Á Barabássy, G Németh Advances in Therapy 38, 3652-3673, 2021 | 54 | 2021 |
| Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial M Fava, S Durgam, W Earley, K Lu, R Hayes, I Laszlovszky, G Németh International clinical psychopharmacology 33 (6), 312-321, 2018 | 52 | 2018 |
Lakshmi Yathamprofessor of psychiatryE-mail megerősítve itt: mail.ubc.ca
